RUNX1 and acute myeloid leukemia: Trials evaluating new clinical settings, such as AML in MRD+ CR after HSCT (NCT04623216), and therapy combinations, such as Sabatolimab plus AZA/VEN (STIMULUS-AML1, NCT04150029), are currently ongoing.